ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2420

Pleiotropic Roles Of Fcγ Receptors Upregulated On Circulating Monocytes In Rheumatoid Arthritis Patients

Masako Tsukamoto1, Katsuya Suzuki2, Keiko Yoshimoto2, Hideto Kameda2 and Tsutomu Takeuchi2, 1Division of Rheumatology, Department of Internal medicine, Keio University School of Medicine, Tokyo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Fc receptors and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis: Human Etiology and Pathogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose: We have previously demonstrated that Fc gamma receptor(FcgR) IIIb(CD16b) polymorphisms were associated with infusion reaction in rheumatoid arthritis(RA) patients. While CD16b is mainly expressed on the surface of neutrophils, mast cells, role of FcgRs on monocytes in RA patients has not been fully elucidated. We hypothesized that FcgRs might play important roles in the interaction between immune complexes and monocytes. Aim of this study is to elucidate role of FcgRs expressed on monocytes and determine their clinical significance in RA patients.

Methods: Heparinized venous blood was obtained from 48 RA patients and 12 healthy controls(HC). Surface expression of CD16(FcgR III), CD16b, CD32(FcgRII) and CD64(FcgRI) molecules on CD14+ cells were measured by flow cytometry. FcgR IIIb are recognized by anti-CD16b antibody(3G8), but for detection of FcgR IIIa, anti-CD16 antibody(1D3) which can react with both FcgR IIIa and IIIb were used. Percentage of positive cells and mean fluorescence intensity(MFI) for each FcgRs were calculated. They were analyzed on association with clinical parameters, such as erythrocyte sedimentation rate(ESR), serum anti-cyclic citrullinated peptide antibody(ACPA) titer.

Results: Both percentages of CD16+ and CD16b+ cells on CD14+ monocytes were significantly increased in RA patients(18.7±8.0% and 8.5±6.5%) compared with HC(13.3±4.9% and 4.4±3.0%)(p=0.025 and p=0.027). These results suggest that CD16 is upregulated, completely different from CD32 on monocytes in RA. Moreover, CD64 MFI on CD14+ monocytes from RA patients(39.0±9.4) was significantly higher than that of HC(30.8±7.1)(p=0.011). Interestingly, CD64 MFI and percentage of CD16+ cells strongly correlated with ESR(p=0.0016 and p=0.035). CD64 expression itself also correlated with ACPA(p=0.044). On the other hand, CD64 MFI correlated with CD16-expressing cells(p=0.049), but didn’t correlated with CD16b(p=0.24).

Conclusion: We found CD16 and CD64 were aberrantly upregulated on CD14+ monocytes in RA patients. Clinically, CD16b upregulation together with its functional polymorphism may participate in adverse reaction such as infusion reaction, and CD64 and CD16a rather may relate to inflammation and autoantibody production in RA.


Disclosure:

M. Tsukamoto,
None;

K. Suzuki,
None;

K. Yoshimoto,
None;

H. Kameda,
None;

T. Takeuchi,

Astra Zeneca K.K., Eli Lilly Japan K.K., Novartis Pharma K.K., Mitsubishi Tanabe Pharma Co., and Asahi Kasei Medical K.K,

5,

AbbVie GK., Bristol–Myers K.K., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., and Takeda Pharmaceutical Co., Ltd.,

8,

AbbVie GK., Astellas Pharma, Bristol–Myers K.K., Chugai Pharmaceutical Co, Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co., Nippon Shinyaku Co., Ltd., Pfizer Japan Inc., Sanofi–Aventis K.K.,

2,

Santen Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd.,

2.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pleiotropic-roles-of-fc%ce%b3-receptors-upregulated-on-circulating-monocytes-in-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology